Artemisinin Combination Therapy

Global Artemisinin Combination Therapy Market to Reach US$940.1 Million by 2030

The global market for Artemisinin Combination Therapy estimated at US$619.9 Million in the year 2024, is expected to reach US$940.1 Million by 2030, growing at a CAGR of 7.2% over the analysis period 2024-2030. Artemether+Lumefantrine, one of the segments analyzed in the report, is expected to record a 8.2% CAGR and reach US$342.7 Million by the end of the analysis period. Growth in the Artesunate+Amodiaquine segment is estimated at 7.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$168.9 Million While China is Forecast to Grow at 11.4% CAGR

The Artemisinin Combination Therapy market in the U.S. is estimated at US$168.9 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$198.8 Million by the year 2030 trailing a CAGR of 11.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.5% and 7.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.8% CAGR.

Global Artemisinin Combination Therapy Market – Key Trends & Drivers Summarized

How Is Artemisinin Combination Therapy Addressing Global Health Challenges?
Artemisinin Combination Therapy (ACT) is recognized as the gold standard for treating malaria, a disease that continues to pose significant public health challenges, particularly in Africa and Southeast Asia. This therapy combines artemisinin derivatives with partner drugs to enhance efficacy and reduce resistance. WHO`s recommendation of ACT as the first-line treatment has driven its widespread adoption across malaria-endemic regions. Governments and non-governmental organizations, such as the Global Fund and UNICEF, are playing a pivotal role in ensuring access to ACTs through large-scale procurement and subsidized distribution programs. Recent innovations include triple-combination therapies designed to combat emerging drug-resistant malaria strains, underscoring the market’s focus on adaptability and resilience.

What Role Does Technology Play in ACT Accessibility?
Technological advancements in drug formulation and production are improving the accessibility of ACTs. Innovations such as nanoparticle-based delivery systems and dispersible tablets have made the therapy more effective and patient-friendly, particularly for children and vulnerable populations. Supply chain optimization, supported by digital tracking systems, ensures timely delivery of ACTs to remote areas. Furthermore, the rise of mobile health (mHealth) platforms is enhancing awareness and adherence to ACT regimens. These platforms allow healthcare workers to educate communities, track treatment progress, and monitor disease outbreaks, contributing to the market`s growth and efficacy.

How Are Global Initiatives Driving Market Expansion?
International collaborations and funding initiatives are critical drivers of the ACT market. Programs like Roll Back Malaria and Medicines for Malaria Venture (MMV) focus on increasing the availability of ACTs while promoting research into new drug combinations to address resistance. The introduction of fixed-dose combinations has simplified administration, improving patient compliance. Additionally, governments in endemic regions are investing heavily in malaria eradication campaigns, which include mass drug administration and subsidies for ACT distribution. These efforts are complemented by private sector involvement, with pharmaceutical companies focusing on scaling up production and ensuring affordability.

What Drives the Growth of the ACT Market?
The growth in the Artemisinin Combination Therapy market is driven by several factors, including the increasing prevalence of malaria and global efforts to eradicate the disease. Rising awareness campaigns have led to improved diagnosis and treatment rates, fueling demand for ACTs. Advances in pharmaceutical manufacturing have reduced production costs, making these therapies more accessible in low-income regions. The adoption of combination therapies to combat resistance and the expansion of public-private partnerships are further enhancing market reach. Additionally, the integration of ACT distribution with other healthcare initiatives, such as vaccination programs, maximizes the therapy`s impact, ensuring robust growth for the market.

SCOPE OF STUDY:

The report analyzes the Artemisinin Combination Therapy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Type (Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate, Other Types)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

• Ajanta Pharma Ltd.
• Bliss GVS Pharma Ltd.
• DENK PHARMA GmbH & Co. KG
• Hovid Berhad
• Ipca Laboratories Ltd.
• KPC Pharmaceuticals, Inc.
• Macleods Pharmaceuticals Ltd.
• Novartis AG
• Sanofi S.A.
• Shanghai Desano Bio-Pharmaceutical Co., Ltd.
• Shanghai Fosun Pharmaceutical (Group) Co. Ltd.
• Shin Poong Pharm Co. Ltd.
• Sumaya Biotech GmbH & Co. KG

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.